From the provided abstract [33], it is not clear whether the differences in a treatment response were observed between HER2-mutant NSCLC and HER2-overexpressing NSCLC (2+ and 3+ scores by IHC). The gene discussed is ERBB2; the disease is non-small cell lung carcinoma.